Jun 2026 (Q2 FY26) — Aug 10, 2026
Bionano Q2 FY26 — Strong Consumable Growth Driven by Clinical Adoption
Read the full callBionano (BNGO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Bionano earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 8.2 | +21.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -88.3 | +27.5 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.4 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.22 −2.40% · −$0.03
Performance −35.8% 1Y
1Y: $1.9 on 17 Oct 2025 → $1.22. High $1.98 (20 Oct 2025), low $1.06 (30 Jul 2026).
- Previous close
- $1.25
- 52-week range
- $1.06 – $1.98
- One year
- −38.38%
Overview
- Symbol
- BNGO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Bionano earnings calls (BNGO)
Financials
What the filings say
Net profit, year on year: −8% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 6 | 8 | 6 | 7 | 7 | 8 | 7 | 8 |
| Expenses | 35 | 15 | 11 | 11 | 12 | 12 | 11 | 12 |
| Operating profit | -44 | -12 | -8 | -8 | -9 | -9 | -8 | -7 |
| Operating margin | −722.9% | −146.3% | −131.1% | −115.8% | −115.9% | −107.4% | −118.1% | −88.3% |
| Other income | -0 | -8 | 5 | 1 | 0 | 1 | -0 | -0 |
| Profit before tax | -44 | -20 | -3 | -7 | -8 | -8 | -8 | -7 |
| Tax rate | −0.1% | 0.0% | −0.2% | −0.1% | −0.2% | −0.5% | −0.1% | −0.1% |
| Net profit | -44 | -20 | -3 | -7 | -9 | -8 | -8 | -7 |
| EPS ($ per share) | -30.92 | — | -1.15 | -1.99 | -1.59 | — | -0.76 | -0.64 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -73 | -103 | -144 | -216 | -349 | -581 | -693 | -720 |
| Total liabilities | 15 | 27 | 25 | 40 | 58 | 118 | 41 | 29 |
| Fixed assets | 2 | 2 | 5 | 10 | 18 | 23 | 19 | 15 |
| Total assets | 25 | 30 | 60 | 377 | 308 | 214 | 77 | 74 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -20 | -30 | -38 | -72 | -125 | -125 | -69 | -16 |
| Cash from investing | -0 | -0 | -2 | -278 | 83 | 24 | 74 | -13 |
| Cash from financing | 36 | 30 | 62 | 336 | 23 | 114 | -14 | 24 |
| Net cash flow | 16 | 1 | 21 | -14 | -19 | 13 | -9 | -5 |
| Capital expenditure | -0 | -0 | 0 | — | — | — | — | — |
| Free cash flow | -20 | -30 | -38 | — | — | — | — | — |
Insider filings
11 filings between Feb 17, 2026 and Sep 4, 2026.
Open market
decisions to buy or sellPurchases
$9.7K
2 purchases by 1 insider
Sales
None
No insider sold shares.
Compensation
not trading decisions- 9
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Luderer Albert | $9.7K | — | Sep 4, 2026 |
Latest filings (26)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 4, 2026 | Luderer Albert Interim Chief Executive | Purchase | 4,000 | $4.8K |
| Aug 21, 2026 | Luderer Albert Interim Chief Executive | Purchase | 4,000 | $4.9K |
| Jun 3, 2026 | Chaubey Alka CHIEF MEDICAL OFFICER | Tax withheld | 24 | $31 |
| Jun 3, 2026 | Dixon Jonathan V. GENERAL COUNSEL | Tax withheld | 24 | $31 |
| Jun 3, 2026 | Adamchak Mark Principal Accounting Officer | Tax withheld | 7 | $9 |
| Jun 3, 2026 | OLDAKOWSKI MARK CHIEF OPERATING OFFICER | Tax withheld | 27 | $35 |
| Feb 17, 2026 | OLDAKOWSKI MARK CHIEF OPERATING OFFICER | Tax withheld | 20 | $22 |
| Feb 17, 2026 | Chaubey Alka CHIEF MEDICAL OFFICER | Tax withheld | 18 | $20 |
| Feb 17, 2026 | Dixon Jonathan V. GENERAL COUNSEL | Tax withheld | 6 | $7 |
| Feb 17, 2026 | Adamchak Mark Principal Accounting Officer | Tax withheld | 3 | $3 |
| Feb 17, 2026 | Holmlin R. Erik PRESIDENT AND CEO | Tax withheld | 51 | $56 |
| Sep 11, 2025 | OLDAKOWSKI MARK Chief Operating Officer | Tax withheld | 59 | $240 |
| Sep 11, 2025 | Chaubey Alka Chief Medical Officer | Tax withheld | 51 | $207 |
| Jun 3, 2025 | Holmlin R. Erik President and CEO | Tax withheld | 75 | $277 |
| Jun 3, 2025 | Chaubey Alka Chief Medical Officer | Tax withheld | 24 | $89 |
| Jun 3, 2025 | Adamchak Mark Principal Accounting Officer | Tax withheld | 7 | $26 |
| Jun 3, 2025 | OLDAKOWSKI MARK Chief Operating Officer | Tax withheld | 27 | $100 |
| Jun 3, 2025 | Dixon Jonathan V. General Counsel | Tax withheld | 25 | $92 |
| Mar 14, 2025 | Holmlin R. Erik President and CEO | Tax withheld | 198 | $687 |
| Feb 15, 2025 | Chaubey Alka Chief Medical Officer | Tax withheld | 18 | $103 |
| Feb 15, 2025 | Holmlin R. Erik President and CEO | Tax withheld | 51 | $292 |
| Feb 15, 2025 | Dixon Jonathan V. General Counsel | Tax withheld | 6 | $34 |
| Feb 15, 2025 | Adamchak Mark Principal Accounting Officer | Tax withheld | 4 | $23 |
| Feb 15, 2025 | OLDAKOWSKI MARK Chief Operating Officer | Tax withheld | 20 | $115 |
| Sep 11, 2024 | OLDAKOWSKI MARK Chief Operating Officer | Tax withheld | 3,568 | $1.7K |
| Sep 11, 2024 | Chaubey Alka Chief Medical Officer | Tax withheld | 3,075 | $1.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Bionano Genomics, Inc.
Free account. Everything above stays public.
Write why you follow Bionano Genomics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading